AI / data analytics / healthtech / informatics

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Bioengineering #Business #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Organic chemistry #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Sequencing #System biology #Target validation #Toxicology

Natural Product Pharmaceuticals – The third generation

Natural Product Pharmaceuticals – The third generation By Dr Melanie McCullagh Compounds derived from natural products have made a big impact on the pharmaceutical industry. Of the 1,010 NCEs approved between January 1981 and June 2006, 43 were unaltered natural products (NPs) and a further 232 (23%)… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Flow Cytometry #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Metabolomics #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

High Content Screening – The next challenge: effective data mining and exploration

High Content Screening – The next challenge: effective data mining and exploration By Dr Kurt Zingler and Dr Stephan Heyse The use of high content screening within HTS is growing and with many past hurdles now overcome, the need for effective tools for data analysis is becoming paramount. Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biochemistry #Biomarkers #Business #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Lead discovery #Oncology #Pathology #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #RNA #Toxicology

Biomarker Signal Definition

Biomarker Signal Definition By Dr Gordon F. Kapke and Dr Nigel Brown Due to the numerous challenges in the industry, pharmaceutical companies are examining all aspects of the drug development process and rebuilding their associated business models as necessary. Companies need to improve… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Biologics / Biotechnology #Business #Drug development #Drug discovery #Drug targets #Lead discovery #Regulatory #RNA #Translational #Translational chemistry

How Pharma Companies Manage in a Tough Financial Climate

How Pharma Companies Manage in a Tough Financial Climate By Paul Branthwaite Maintaining knowledge and experience internally is a challenge in today’s financial climate, in SMEs and in big pharma. This article provides some tips on how companies can maintain their best staff or find reliable alternative… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #High Content Screening #Lead discovery #Lead optimisation #Preclinical #Regulatory #RNA

Outsourcing for Innovation Takes on New Meaning

Outsourcing for Innovation Takes on New Meaning By Richard Boehner Large pharmaceutical companies are moving quickly to outsource their drug discovery operations, predominantly to lower costs. This article argues that if outsourcing is done to capture value, ie developing and preserving intellectual property as a key competitive… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Lead discovery #Lead optimisation #PCR #Regulatory #RNA #Sequencing #Stem cells #Target validation #Toxicology

qPCR Assays – End user practices and latest vendor offerings

qPCR Assays – End user practices and latest vendor offerings By Dr John Comley This review provides an insight into real-time quantitative PCR (qPCR) assays today. Using end-user feedback it investigates interest in the targets for qPCR applications; primary application areas for qPCR… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Clinical specialities #Clinical trials #Gene therapy #Pathology #Regulatory #RNA #Therapeutics #Toxicology

A Bronchoscopically Administered Therapeutic Approach to Advanced Emphysema

A Bronchoscopically Administered Therapeutic Approach to Advanced Emphysema By Dr Edward E. Berger Emphysema is a progressive, debilitating disease that affects approximately 4.1 million people in the United States or roughly 1% of the US population. The disease is characterised by destruction of lung tissue as a… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Patent Law #PCR #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

High Throughput Screening in Academia – Drug discovery initiatives at the University of Kansas

High Throughput Screening in Academia – Drug discovery initiatives at the University of Kansas By Dr P McDonald, Dr Roy, Byron Taylor, Ashleigh Price, Dr Sittampalam, Dr Scott Weir, Dr Chaguturu Academia has historically been involved in exploring the fundamental aspects of the disease targets and in… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Cell / tissue culture #Cell culture #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene therapy #Genomics #Immunology #Lead discovery #Medicinal chemistry #Molecular medicine #Precision medicine #Preclinical #Regulatory #RNA #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Next Generation Immunoassay Systems and the Revival of Protein Biomarkers

Next Generation Immunoassay Systems and the Revival of Protein Biomarkers By Dr John Todd and Dr Sara J. Agee Proteins are the machinery that drive most biological processes; however, measuring their concentrations at low levels has been historically impeded by a lack of appropriately sensitive technology. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biochemistry #Bioengineering #Business #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Lead discovery #Lead optimisation #Oncology #Pharmokinetics #Preclinical #Screening #System biology #Systems biology #Therapeutics

Prediction versus Attrition in Drug Discovery & Development

Prediction versus Attrition in Drug Discovery & Development By Professor Malcolm Young The research-intensive part of the pharmaceutical industry is facing unusual commercial difficulties, whose elements are now well-known. A substantial number of very valuable drugs have gone, or are about to go,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cellular assays #Drug development #High throughput screening #Immunology #Pharmacology #Preclinical #Regulatory #RNA #Screening #Therapeutics #Toxicology

Challenges in Transferring Bioanalytical Methods

Challenges in Transferring Bioanalytical Methods By Dr Chris Beaver Drug development is arduous and expensive with any delay to market resulting in significant financial impact. Delays at any stage of the process cause challenges to programmes, however, some are easier to predict and plan for than others. Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Orphan drugs #PCR #Preclinical #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology

Progress in the Implementation of Label-Free Detection – Cell-based assays

Progress in the Implementation of Label-Free Detection – Cell-based assays By Dr John Comley Progress made in the use of impedance and optical grating technologies for label-free detection of cell-based assays where examined in HTStec’s recent Cell-Based Label-Free Detection Trends report. Uniquely all… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biomarkers #Business #Cellular assays #Chemistry #Clinical specialities #Drug discovery #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Microbiology #PCR #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology

Emerging Real-time PCR Applications

Emerging Real-time PCR Applications Dr Mikael Kubista Since its introduction on the commercial market little more than 10 years ago, real-time PCR has become the main technical platform for nucleic acid detection in research and development, as well as in routine diagnostics. In 2007… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Cellular assays #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #RNA #Screening #Stem cells #System biology #Target validation

Integrating HTS and Fragment-based Drug Discovery

Integrating HTS and Fragment-based Drug Discovery By Dr John Barker, Dr Thomas Hesterkamp and Dr Mark Whittaker High-Throughput Screening and Fragment Based Drug Discovery have been considered as alternative approaches to drug discovery for enzyme targets. HTS tends to be a rather quick way… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Automation / robotics #Biomarkers #Cell culture #Cellular & Molecular biology #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Microfluidics #Molecular medicine #Precision medicine #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Target validation #Therapeutics

Data Overflow Progress in Automating and Streamlining Data

Data Overflow Progress in Automating and Streamlining Data By Peer Staehler The genomic world moves faster and faster. The pool of data has exploded exponentially in the past few years due to the growing knowledge about the relevance of genomic findings for medicine and the environment. Like all… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #Imaging #Lead discovery #Molecular medicine #Oncology #Preclinical #Regulatory #System biology #Systems biology #Target validation

The Potential of Molecular Imaging for Drug Discovery & Development

The Potential of Molecular Imaging for Drug Discovery & Development By Dr Ken Rubenstein By combining cutting-edge biomedical research with the time-proven ability to visualise the unseen, the rapidly emerging field of molecular imaging promises to open new vistas for a wide range of individuals, from basic researchers… Read More

#Archive